Yili Chuannig Biotech - Public Comps and Valuation Multiples

Yili Chuannig Biotech Overview

About Yili Chuannig Biotech

Yili Chuannig Biotechnology Co Ltd adopts the most advanced and mature international biological fermentation, chemical extraction, enzymatic hydrolysis, control and energy saving, and environmental protection technology. The main products of the company include erythromycin thiocyanate, cephalosporin intermediates, penicillin intermediates, and crude ursodeoxycholic acid.

Founded

2010

HQ

Employees

n/a

Website

klcnsw.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$3.9B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Yili Chuannig Biotech Financials

Yili Chuannig Biotech has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Yili Chuannig Biotech achieved revenue of $665M and an EBITDA of $242M.

Yili Chuannig Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Yili Chuannig Biotech valuation multiples based on analyst estimates

Yili Chuannig Biotech P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$665M	n/a	XXX	XXX	XXX
Gross Profit	$98.9M	$131M	XXX	XXX	XXX
Gross Margin	15%	NaN%	XXX	XXX	XXX
EBITDA	$242M	n/a	XXX	XXX	XXX
EBITDA Margin	36%	NaN%	XXX	XXX	XXX
Net Profit	$15.3M	$56.7M	XXX	XXX	XXX
Net Margin	2%	NaN%	XXX	XXX	XXX
Net Debt	$314M	$107M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Yili Chuannig Biotech Stock Performance

As of April 15, 2025, Yili Chuannig Biotech's stock price is CNY 12 (or $2).

Yili Chuannig Biotech has current market cap of CNY 27.1B (or $3.7B), and EV of CNY 28.4B (or $3.9B).

See Yili Chuannig Biotech trading valuation data

Yili Chuannig Biotech Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.9B	$3.7B	XXX	XXX	XXX	XXX	$0.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Yili Chuannig Biotech Valuation Multiples

As of April 15, 2025, Yili Chuannig Biotech has market cap of $3.7B and EV of $3.9B.

Yili Chuannig Biotech's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Yili Chuannig Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for Yili Chuannig Biotech and 10K+ public comps

Yili Chuannig Biotech Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$3.9B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	XXX	XXX
P/E	n/a	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Yili Chuannig Biotech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Yili Chuannig Biotech Valuation Multiples

Yili Chuannig Biotech's NTM/LTM revenue growth is n/a

Yili Chuannig Biotech's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Yili Chuannig Biotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate Yili Chuannig Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for Yili Chuannig Biotech and other 10K+ public comps

Yili Chuannig Biotech Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	n/a	XXX	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	n/a	XXX	XXX	XXX	XXX
Opex per Employee	n/a	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	0%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	1%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	1%	XXX	XXX	XXX	XXX
Opex to Revenue	6%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry